TopStockBD
DSE TodayToday's prices & moversToday's NewsAll company news, last dayMarket AnalysisPulse, sentiment, trendsDSE Top 20Momentum leadersPopular StocksMost-traded today
TopStock AIChat: picks, market & answersRankingsScored leaderboardDaily TipsFresh signals every dayFind My StocksPersonalized pickerStock ListsReady-made listsBrowse All StocksFull A–Z table
BlogsEnglish guidesবাংলা ব্লগBangla guidesBehind the ScoreHow we rank stocks
WatchlistPortfolioPrice AlertsSign InSign Up
Menu
MarketsDSE TodayToday's NewsMarket AnalysisDSE Top 20Popular Stocks
DiscoverTopStock AIRankingsDaily TipsFind My StocksStock ListsBrowse All Stocks
LearnBlogsবাংলা ব্লগBehind the Score
YouWatchlistPortfolioPrice AlertsSign InCreate Account
TopStockBD

Fundamental scoring for Dhaka's market

[email protected]

Explore

  • Stock Rankings
  • Market Analysis
  • DSE Today
  • Browse Stocks
  • Stock Lists

Learn

  • Beginner's Guide
  • বাংলা ব্লগ
  • Watchlist
  • Portfolio
  • Behind the Score

Company

  • About Us
  • Contact
  • Privacy Policy
  • Disclaimer

TopStockBD covers DSE share price today, Dhaka Stock Exchange (DSEX) live data, Bangladesh stock market rankings, DSE news, BD stock market signals, and DSE share price list — free fundamental analysis for every listed company. Learn how to invest in DSE, how to buy shares in Bangladesh, how to open a BO account, find best stocks in Bangladesh, dividend stocks, blue chip stocks Bangladesh, and undervalued stocks DSE using P/E ratio and fundamental analysis.

© 2026 TopStockBD. All rights reserved.

Not investment advice. For informational purposes only.

HomeDSEDiscoverWatchlist
  1. Home
  2. /
  3. Rankings
  4. /
  5. RENATA

Renata PLC

RENATAPharmaceuticals & ChemicalsCategory A

Last Price

460.5৳
▲+0.20% today
Low ৳378.6In its normal rangeHigh ৳530.3

Where today's price sits in its 52-week range

The Price Story

এক নজরে

Renata PLC ওষুধ ও রসায়ন খাতের একটি কোম্পানি। সব মিলিয়ে কোম্পানিটি মোটামুটি অবস্থায় আছে (আমাদের বিশ্লেষণে 100-এর মধ্যে 53)। কোম্পানিটি লাভ করছে, তবে গত বছরের তুলনায় মুনাফা কিছুটা কমেছে। একই ধরনের অন্যান্য কোম্পানির তুলনায় এই শেয়ারটির দাম এখন তুলনামূলক কম। কোম্পানিটি কিছুটা ডিভিডেন্ড দেয় (বছরে প্রায় 1.2%)।

এটি শিক্ষামূলক তথ্য, বিনিয়োগ পরামর্শ নয়।

RENATAWatch 53
Rank #97 of 361Wait for nowWatch list
৳461+0.2%
VerdictHealthValueNumbersFinancialsMomentumSignalsPeersOwnersNews
TopStockBDAnalysis

Renata PLC

RENATAPharmaceuticals & ChemicalsLatest Price: ৳460.5
Fundamental Score
53/ 100

Wait & Watch

Watch list

Average company, very little trading

  • The company's profits and balance sheet are average — not strong, not weak. The share price is also quiet, not moving much in either direction. There is no clear reason to buy or sell — better to wait and watch.
  • The share price looks cheaper now than its average over the past few years.
topstockbd.comDSE Stock Analysis
⭐

Featured in our stock lists

💊Best Pharma Stocks#6🇧🇩Top Stocks 2025#14📈Highest EPS Stocks#18

The Health Check

Five quick checks that tell you whether this company is healthy, fairly priced, and worth holding.

Is the Price Right?

Priced about fairly — neither a bargain nor expensive.

P/E Ratio

23.8

Price per ৳1 of yearly earnings

Dividend Yield

1.20%

Annual cash return on the price

P/B Ratio

1.5

Price per ৳1 of net assets

Trading at 23.8 — below its 5-year average of 32.6.

Key Numbers

The raw figures behind the verdict — for the curious.

EPS

৳19.36

Earnings per share (latest year)

P/E Ratio

25.2

Price you pay per ৳1 of earnings

Dividend Yield

1.20%

Annual cash return on the price

Reserve & Surplus

৳3,391 Cr

Company's accumulated savings

Total Loan

৳1,888 Cr

Outstanding debt the company carries

Profits & Dividends

Are they making money — and do they share it with shareholders?

Yearly Profit

Net profit per year

Made a profit every year for 5 years.

Earnings Per Share

Profit you earn per share

Profitable per share every year for 5 years.

Yearly Cash Dividend

% of face value

📢 New 55% dividend just declared — record 17 Nov 2025

Paid a dividend every year for 5 years running.

The deeper numbers — revenue, margins, debt and cash quality over the years.

Recent Momentum

What the share price has been doing over the last week.

Flat

Up 1.0% in the past week, on lighter-than-usual trading.

Past week

+1.0%

Price move over 7 days

Vs market

+0.3%

Ahead/behind the DSEX index

Trading volume

0.6×

vs its normal volume

Up days

5/7

Green days this week

52-week spot

54%

Position in 1-year range

Trades around ৳2.0 Cr a day on average over the past week.

Signals at a Glance

The good signs and the things to keep an eye on.

Good signs

  • ✓Made profits in 4 out of the last 5 years
  • ✓Generates real cash from its day-to-day business
  • ✓Pays a dividend every year, like clockwork
  • ✓Currently priced cheaper than its own history

How It Stacks Up

RENATA scores below the other strong names in its sector shown here.

Stock
MARICO84৳2,731+0.1%14.6+14.1%+78.4%
SQURPHARMA82৳221-0.8%8.2+5.4%+14.8%
KOHINOOR78৳513+0.9%30.1+1.3%+26.2%
RECKITTBEN74৳3,326+0.2%19.2+5.2%+45.4%
ACMELAB73৳84.5+0.4%7.4+4.1%+9.1%
RENATA53৳461+0.2%23.8+1.2%+10.7%

Who Owns It

Who's behind this company — and how committed are they? As of Mar 2026, compared with Jun 2025.

Owners (Sponsors / Directors)51.3%
Institutions▲ 0.522.4%
Foreign Investors▼ 1.618.3%
General Public8.0%

Worth watching — foreign investors cut their stake from 19.9% to 18.3% since Jun 2025. Keep an eye on why.

Owners (sponsors) hold 51% — heavily invested in the company's success.

What's New

Recent news and announcements about this company.

The company has informed that it has received approval for its Levothyroxine Sodium tablets under the EU Decentralised Procedure (DCP) in Ireland, Germany, Italy, Poland, Portugal and Malta. The product will be manufactured at Renata's EU GMP-approved potent product facility. Renata PLC intends to support safe and reliable access to Levothyroxine in the newly approved EU markets.
(Q3 Un-audited): Consolidated EPS was Tk. 6.81 for January-March 2026 as against Tk. 5.12 for January-March 2025; Consolidated EPS was Tk. 20.39 for July 2025-March 2026 as against Tk. 15.95 for July 2024-March 2025. Consolidated NOCFPS was Tk. 22.40 for July 2025-March 2026 as against Tk. 21.76 for July 2024-March 2025. Consolidated NAV per share was Tk. 320.02 as on March 31, 2026, and Tk. 305.49 as on June 30, 2025.
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 29, 2026 at 2:30 PM to consider, among others, Un-Audited Financial Statements for the Third Quarter (Q3) period ended March 31, 2026.